Cargando…
Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia
Background and Objectives: To find low-cost markers that can identify the hepatitis C virus cirrhotic patients that are at risk for long-term severe adverse liver effects (ascites, ascites or upper gastrointestinal bleeding, hepatocellular carcinoma), after treatment. There is established evidence f...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865508/ https://www.ncbi.nlm.nih.gov/pubmed/36676770 http://dx.doi.org/10.3390/medicina59010146 |
_version_ | 1784875855611166720 |
---|---|
author | Omer, Secil Iftime, Adrian Constantinescu, Ileana Dina, Ion |
author_facet | Omer, Secil Iftime, Adrian Constantinescu, Ileana Dina, Ion |
author_sort | Omer, Secil |
collection | PubMed |
description | Background and Objectives: To find low-cost markers that can identify the hepatitis C virus cirrhotic patients that are at risk for long-term severe adverse liver effects (ascites, ascites or upper gastrointestinal bleeding, hepatocellular carcinoma), after treatment. There is established evidence for the benefits of treating hepatitis C virus cirrhotic patients, but there is still some need for clarification concerning the real impact on the long-term evolution after achieving sustained virological response; there is no general consensus in the literature about identifying the patients that do not improve post-treatment. Materials and Methods: Our retrospective analysis investigated the long-term (2 years) evolution of 46 patients with cirrhosis with thrombocytopenia, previously infected with VHC, treated and who obtained an SVR after DAA treatment. Results: Despite the overall improvement, 8.7% patients developed hepatocellular carcinoma and 6.5% patients ascites/upper GI bleeding. We found that FIB-4, MELD and AFP changes at 1 year were the most significant predictors for these outcomes. Additionally, a drop in leukocyte count after 1 year seemed to indicate a risk for hepatocellular carcinoma, but this was not consistent. Conclusions: It might be beneficial to intensify the surveillance for post-treatment adverse liver effects for the patients with these marker changes at 1 year. |
format | Online Article Text |
id | pubmed-9865508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98655082023-01-22 Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia Omer, Secil Iftime, Adrian Constantinescu, Ileana Dina, Ion Medicina (Kaunas) Article Background and Objectives: To find low-cost markers that can identify the hepatitis C virus cirrhotic patients that are at risk for long-term severe adverse liver effects (ascites, ascites or upper gastrointestinal bleeding, hepatocellular carcinoma), after treatment. There is established evidence for the benefits of treating hepatitis C virus cirrhotic patients, but there is still some need for clarification concerning the real impact on the long-term evolution after achieving sustained virological response; there is no general consensus in the literature about identifying the patients that do not improve post-treatment. Materials and Methods: Our retrospective analysis investigated the long-term (2 years) evolution of 46 patients with cirrhosis with thrombocytopenia, previously infected with VHC, treated and who obtained an SVR after DAA treatment. Results: Despite the overall improvement, 8.7% patients developed hepatocellular carcinoma and 6.5% patients ascites/upper GI bleeding. We found that FIB-4, MELD and AFP changes at 1 year were the most significant predictors for these outcomes. Additionally, a drop in leukocyte count after 1 year seemed to indicate a risk for hepatocellular carcinoma, but this was not consistent. Conclusions: It might be beneficial to intensify the surveillance for post-treatment adverse liver effects for the patients with these marker changes at 1 year. MDPI 2023-01-11 /pmc/articles/PMC9865508/ /pubmed/36676770 http://dx.doi.org/10.3390/medicina59010146 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Omer, Secil Iftime, Adrian Constantinescu, Ileana Dina, Ion Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia |
title | Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia |
title_full | Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia |
title_fullStr | Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia |
title_full_unstemmed | Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia |
title_short | Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia |
title_sort | low-cost predictors for liver function and clinical outcomes after sustained virological response in patients with hcv-related cirrhosis and thrombocytopenia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865508/ https://www.ncbi.nlm.nih.gov/pubmed/36676770 http://dx.doi.org/10.3390/medicina59010146 |
work_keys_str_mv | AT omersecil lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia AT iftimeadrian lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia AT constantinescuileana lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia AT dinaion lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia |